Full-Time
Field Application Specialist
Sartorius
1,001-5,000 employees
Bioprocess and laboratory solutions provider
No salary listed
Bengaluru, Karnataka, India
In Person
 Biology & Biotech (1) |
|---|
- Master’s degree in biotechnology, biochemistry or similar life science disciplines or Engineering degree in biotechnology or biochemical engineering
- 4 - 6 years of experience in Life Science Industry in process development / Upstream manufacturing in Biopharmaceutical industry
- Proven skills of relevant process unit operations in cGMP Bioprocessing, especially upstream handling
- Support the Sales organization on existing products through product presentations, demonstrations and application studies, and on new products in close collaboration with product management through beta sites testing and demonstrations
- Support Sales in the customer process and URS analysis, and generate application trials to help designing optimized products in line with the application requirements
- Assist customers for first product installation and initial start-up, and ensure the training of the customer
- Support Quality Department in the quality complaint process by troubleshooting and analyzing customers processes for better investigation and resolution
- The major responsibilities are to ensure successful design, validation and implementation of our products by supporting sales for product design, product positioning and demonstration, and supporting customers for application development work, initial startups and training
- Good Market Knowledge (Customers and Competitors)
- Excellent teamwork skills and proven ability to also work with cross-functional teams without formal authority
Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Göttingen, Germany
Founded
1870
Your Connections
People at Sartorius who can refer or advise you
Simplify's Take
What believers are saying
- Q4 2025 revenue grew 7.6% to over €3.5 billion.
- The Eveo platform targets CAR-T costs down 90% and output quadrupled.
- MatTek adds $20 million-plus sales and 3D microtissue models for preclinical workflows.
What critics are saying
- Lab Products and Services grew just 0.2% in Q4 2025.
- The €650 million bond matures in autumn 2026 after the new €500 million placement.
- Eveo's 2027 deliveries leave validation risk unresolved until customer orders begin.
What makes Sartorius unique
- Founded in 1870, Sartorius built precision balances before bioprocessing.
- Bioprocess Solutions leads with filtration, fermentation, cell culture, and fluid management.
- The 2007 Stedim merger created a global single-use bioprocessing platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget
Company News
May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.
Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.
Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.
Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.
Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.